This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

NCT01035255 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

8442

Enrollment

INDUSTRY

Sponsor class

Stopped Early termination was approved due to compelling efficacy of LCZ696 in patients with HF \& reduced EF after final pre-specified interim analysis 28-Mar-2014.

Conditions

Heart Failure With Reduced Ejection Fraction

Interventions

DRUG: LCZ696 200 mg BID
DRUG: Enalapril 10 mg BID

Sponsor

Novartis Pharmaceuticals